{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:12:15Z","timestamp":1760616735104,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T00:00:00Z","timestamp":1381363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.rmed.2013.06.007","type":"journal-article","created":{"date-parts":[[2013,7,13]],"date-time":"2013-07-13T00:01:11Z","timestamp":1373673671000},"page":"1709-1721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost effectiveness of adding budesonide\/formoterol to tiotropium in COPD in four Nordic countries"],"prefix":"10.1016","volume":"107","author":[{"given":"Rune","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannu","family":"Kankaanranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Bjermer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Arnetorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Hedegaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Stenling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2013.06.007_bib1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.rmed.2010.09.019","article-title":"Prevalence of COPD in Copenhagen","volume":"105","author":"Fabricius","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/15412550802522635","article-title":"The prevalence of chronic obstructive pulmonary disease among danes aged 45-84 years: population-based study","volume":"5","author":"Hansen","year":"2008","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2013.06.007_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4104\/pcrj.2011.00024","article-title":"The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality","volume":"20","author":"Kinnula","year":"2011","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.rmed.2013.06.007_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/15412550500218122","article-title":"Chronic obstructive pulmonary disease in Finland: prevalence and risk factors","volume":"2","author":"Kotaniemi","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.rmed.2013.06.007_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1752-699X.2009.00137.x","article-title":"Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general population","volume":"4","author":"Hvidsten","year":"2010","journal-title":"Clin Respir J"},{"key":"10.1016\/j.rmed.2013.06.007_bib6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/thx.2005.043943","article-title":"Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study","volume":"60","author":"Johannessen","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2013.06.007_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.rmed.2005.04.029","article-title":"Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking report from the obstructive lung disease in Northern Sweden Studies","volume":"100","author":"Lindberg","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/rmed.2003.1446","article-title":"Not 15 but 50% of smokers develop COPD?\u2013Report from the obstructive lung disease in Northern Sweden Studies","volume":"97","author":"Lundback","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(07)61377-4","article-title":"International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study","volume":"370","author":"Buist","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2013.06.007_bib10","first-page":"2095","article-title":"The costs of COPD in Finland in 2006","volume":"64","author":"Tynkkynen","year":"2009","journal-title":"Finnish Med J"},{"key":"10.1016\/j.rmed.2013.06.007_bib11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1378\/chest.122.6.1994","article-title":"Costs of COPD in Sweden according to disease severity","volume":"122","author":"Jansson","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2013.06.007_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1053\/rmed.2002.1334","article-title":"The costs of exacerbations in chronic obstructive pulmonary disease (COPD)","volume":"96","author":"Andersson","year":"2002","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.rmed.2006.06.020","article-title":"The cost of treating patients with COPD in Denmark\u2013a population study of COPD patients compared with non-COPD controls","volume":"101","author":"Bilde","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1183\/09031936.00166108","article-title":"Present and future costs of COPD in Iceland and Norway: results from the BOLD study","volume":"34","author":"Nielsen","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.007_bib15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1164\/rccm.200712-1869OC","article-title":"Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study","volume":"178","author":"Celli","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib16","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1185\/03007990903465926","article-title":"Association between incidence of acute exacerbation and medication therapy in patients with COPD","volume":"26","author":"Suh","year":"2010","journal-title":"Curr Med Res Opin"},{"year":"2010","series-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","author":"Global Initiative for Chronic Obstructive Lung Disease (GOLD)","key":"10.1016\/j.rmed.2013.06.007_bib18"},{"year":"2004","series-title":"Chronic obstructive pulmonary disease (Clinical guideline 12)","author":"National Institute for Health and Clinical Excellence","key":"10.1016\/j.rmed.2013.06.007_bib19"},{"key":"10.1016\/j.rmed.2013.06.007_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1164\/rccm.200904-0492OC","article-title":"Efficacy and tolerability of budesonide\/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease","volume":"180","author":"Welte","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/thx.2007.089557","article-title":"Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD","volume":"63","author":"Najafzadeh","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2013.06.007_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1183\/09031936.03.00083703","article-title":"One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease","volume":"23","author":"Oostenbrink","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.007_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00019053-200725080-00007","article-title":"A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease","volume":"25","author":"Rutten-van Molken","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.rmed.2013.06.007_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/11590380-000000000-00000","article-title":"Cost effectiveness of budesonide\/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives","volume":"29","author":"Mittmann","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.rmed.2013.06.007_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2165\/00019053-199712060-00003","article-title":"The Danish approach to standards for economic evaluation methodologies","volume":"12","author":"Alban","year":"1997","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.rmed.2013.06.007_bib26","unstructured":"Decree of the Ministry of Social Affairs and Health on applications and price notifications made to the Pharmaceuticals Pricing Board (201\/2009) \u2013 appendix: guidelines for preparing a health economic evaluation (360\/2011). At: http:\/\/www.finlex.fi\/ [accessed May 2011]."},{"year":"2005","series-title":"Norwegian guidelines for pharmacoeconomic analysis in connection with applications for reimbursement","author":"Norwegian Medicines Agency","key":"10.1016\/j.rmed.2013.06.007_bib27"},{"year":"2003","series-title":"General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2)","author":"The Dental and Pharmaceutical Benefits Agency","key":"10.1016\/j.rmed.2013.06.007_bib28"},{"year":"2010","series-title":"Diagnostik og stadieinddeling af KOL","author":"Dansk L\u00e6gemiddel Information","key":"10.1016\/j.rmed.2013.06.007_bib29"},{"key":"10.1016\/j.rmed.2013.06.007_bib30","first-page":"2290","article-title":"Den norske l\u00e6geforenings strategigruppe for KOLS. Veileder til diagnose, behandling och forebygging av kronisk obstruktiv lungesykdom (KOLS)","volume":"122","author":"Stavem","year":"2002","journal-title":"Tidsskr Nor L\u00e6geforen"},{"key":"10.1016\/j.rmed.2013.06.007_bib31","first-page":"13","article-title":"L\u00e4kemedelsverket. Farmakologisk behandling av kroniskt obstruktiv lungsjukdom (KOL) \u2013 ny rekommendation","volume":"20","year":"2009","journal-title":"Inf Fr\u00e5nL\u00e4kemedelsverket"},{"year":"2009","series-title":"Working group set up by the Finnish medical society Duodecim and the Finnish Respiratory society","key":"10.1016\/j.rmed.2013.06.007_bib32"},{"key":"10.1016\/j.rmed.2013.06.007_bib33","unstructured":"Danish Medicines Agency. Medicinpriser. At: http:\/\/www.medicinpriser.dk\/ [accessed April 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib34","unstructured":"Ministry of Social Affairs and Health. At: http:\/\/www.stm.fi\/ [accessed March 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib35","unstructured":"Norwegian Medicines Agency. At: http:\/\/www.legemiddelverket.no\/ [accessed March 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib36","unstructured":"The Dental and Pharmaceutical Benefits Agency. At: http:\/\/www.tlv.se\/ [accessed March 2011]."},{"year":"2008","series-title":"Old-age pension systems in the Nordic countries","author":"The Nordic Social-Statistical Committee","key":"10.1016\/j.rmed.2013.06.007_bib37"},{"key":"10.1016\/j.rmed.2013.06.007_bib38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.rmed.2009.10.007","article-title":"COPD health care in Sweden - A study in primary and secondary care","volume":"104","author":"Lofdahl","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib39","unstructured":"Organisation for Economic Co-operation and Development (OECD). Unit Labour Costs \u2013 Annual Indicators (ULC_ANN). Labour Compensation per Employee. At: http:\/\/stats.oecd.org\/ [accessed June 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib40","unstructured":"Statistics Finland. Price index of public expenditure, municipal finances 2005=100, healthcare. At: http:\/\/www.stat.fi\/ [accessed June 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib41","unstructured":"Statistics Finland. Price index of public expenditure, municipal finances, old indexes, 2000=100, healthcare. At: http:\/\/www.stat.fi\/ [accessed June 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib42","unstructured":"Statistics Norway. Consumer Price Index (Health and All items), 1998=100. Updated 2011. At: http:\/\/www.ssb.no\/ [accessed April 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib43","unstructured":"Extracted by the Danish Ministry for Health and Prevention (extraction from \u201c2010 cost database with tariff system 2011 after hearing\u201d, extraction performed October 2011)."},{"key":"10.1016\/j.rmed.2013.06.007_bib44","unstructured":"Extracted by The Directorate of Health (\u201cHelsedirokteratet\u201d, hospitalization cost data for 2009, extraction performed May 2011)."},{"year":"2010","series-title":"National Institute for health and Welfare Finland","key":"10.1016\/j.rmed.2013.06.007_bib45"},{"key":"10.1016\/j.rmed.2013.06.007_bib46","unstructured":"The Swedish Association of Local Authorities and Regions. Cost per patient database. At: https:\/\/stat2.skl.se\/kpp\/index.htm [accessed July 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib47","unstructured":"Danish Ministry for Health and Prevention. Ambulante DAGS takster efter h\u00f8ring. At: http:\/\/www.sum.dk\/Sundhed\/DRG-systemet\/Takster.aspx [accessed September 2011]."},{"year":"2008","series-title":"Terveydenhuollon yksikk\u00f6kustannukset Suomessa vuonna 2006","author":"Hujanen","key":"10.1016\/j.rmed.2013.06.007_bib48"},{"key":"10.1016\/j.rmed.2013.06.007_bib49","unstructured":"Norwegian Directorate of Health (\u201cHelsedirokteratet\u201d, personal contact November 2011)."},{"key":"10.1016\/j.rmed.2013.06.007_bib50","unstructured":"The Southern Healthcare Region. Regional rates and allowances 2010. At: http:\/\/www.skane.se\/ [accessed May 2011]."},{"year":"2011","series-title":"Expert opinion provided by working colleague of Leif Bjermer","key":"10.1016\/j.rmed.2013.06.007_bib51"},{"key":"10.1016\/j.rmed.2013.06.007_bib52","unstructured":"GP's Association. Tariff for Danish GPs, as negotiated with Danish Regions (\u201cGruppe 2 takster\u201d) as of 1 October 2010. At: http:\/\/www.laeger.dk [accessed May 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib53","unstructured":"Norges Bank. Annual exchange rates. At: http:\/\/www.norges-bank.no\/ [accessed June 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib54","unstructured":"Sveriges Riksbank. Yearly average exchange rates. At: http:\/\/www.riksbank.com\/ [accessed May 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib55","unstructured":"Danmarks Nationalbank. Annual average exchange rates. At: http:\/\/www.nationalbanken.dk\/ [accessed June 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib56","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","article-title":"Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial","volume":"146","author":"Aaron","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1164\/rccm.200602-244OC","article-title":"Impact of salmeterol\/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease","volume":"175","author":"Kardos","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib59","unstructured":"National Clinical Guideline Centre. Chronic Obstructive Pulmonary Disease: Management of adults with chronic obstructive pulmonary disease in primary and secondary care. National Institute for health and Clinical Excellence 2009. At: http:\/\/www.nice.org.uk\/nicemedia\/pdf\/COPDDraftConsultationGuideline.pdf [accessed May 2011]."},{"key":"10.1016\/j.rmed.2013.06.007_bib60","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2013.06.007_bib61","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1183\/09031936.04.00120603","article-title":"TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol","volume":"24","author":"Vestbo","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2013.06.007_bib62","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/1471-2458-11-612","article-title":"COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population","volume":"11","author":"Fletcher","year":"2011","journal-title":"BMC Public Health"},{"key":"10.1016\/j.rmed.2013.06.007_bib63","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.rmed.2010.08.009","article-title":"Excessive costs of COPD in ever-smokers. A longitudinal community study","volume":"105","author":"Nielsen","year":"2011","journal-title":"Respir Med"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611113002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611113002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:29:21Z","timestamp":1760614161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611113002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0954611113002199"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2013.06.007","relation":{},"ISSN":["0954-6111"],"issn-type":[{"type":"print","value":"0954-6111"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost effectiveness of adding budesonide\/formoterol to tiotropium in COPD in four Nordic countries","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2013.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}